CPhI Online

- Biopharma News

Oxford Biomedica signs LSA with Juno Therapeutics

19 Mar 2020

Cell and gene focused CDMO Oxford Biomedica (OXB) has signed a licence and clinical supply agreement which could be worth up to USD227 million with Juno Therapeutics, the firms announced Wednesday.

The agreement allows Juno Therapeutics – a Bristol Myers Squibb subsidiary -- to use OXB’s LentiVector platform for its CAR-T and TCR-T programmes in oncology and other indications while establishing an initial five-year clinical supply agreement.

Under the terms of the LSA, OXB will receive USD10 million upfront in cash, a potential USD86 million dependent on it reaching certain development and regulatory milestones and a further $131 million in sales-based milestone payments and an undisclosed royalty on net sales of products developed using LentiVector.

OXB will also receive payments from process development and scale-up projects relating to the GMP manufacture of lentiviral vectors for use in clinical trials.

In return, Juno Therapeutics will also have access to OXB’s new 7,800 m2 commercial manufacturing centre OxBox, in Oxford, UK. OXB said it is already working on four undisclosed active projects, with Juno able to add projects in the future.

“This is the second company that has committed to working with us in our new OxBox facility, which we expect to be producing GMP vector by the end of the first half 2020,” said OXB chief executive John Dawson. “Today’s announcement further validates our decision taken in 2018 to invest in and scale up our GMP manufacturing facilities for clinical and commercial viral vector manufacture to support both existing and new partners and customers as well as the expected demand from industry.”

Related Content